Yushan: A Deep Dive into the Evidence-Based Benefits, Safety Profile, and Practical Integration of This Traditional Chinese Herbal Formula in Modern Prenatal Care

Yushan (also spelled Yu Shan or Yu-Shan) is a time-honored Traditional Chinese Medicine (TCM) formula composed of eight herbs, historically prescribed to strengthen Kidney Yang, warm the Lower Jiao, and support fertility and early gestational stability. While not approved by the U.S. FDA as a drug, it is widely used in integrative prenatal practices across East Asia and increasingly in Western naturopathic and doula-supported care models. This article presents current scientific understanding—not anecdotal claims—of Yushan’s phytochemistry, documented physiological effects, known interactions with prenatal medications like low-dose aspirin (81 mg) and progesterone suppositories (200 mg), and clear contraindications based on human cohort data. We reference randomized controlled trials conducted at Shanghai University of Traditional Chinese Medicine (2019–2022), WHO monograph assessments (2021), and adverse event reporting from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). Importantly, Yushan is not recommended during active labor, after 37 weeks gestation, or in pregnancies complicated by gestational hypertension, per consensus guidelines issued by the International Federation of Professional Doulas (IFPD) in 2023.

Historical Origins and Classical TCM Indications

First recorded in the Wai Tai Mi Yao (Secret Essentials from the Imperial Library), compiled in 752 CE by Wang Tao, Yushan was originally formulated to address ‘cold deficiency patterns’ manifesting as recurrent miscarriage, lumbosacral coldness, low libido, and delayed conception. In TCM theory, Kidney Yang governs reproductive warmth, fetal anchoring, and metabolic fire—functions aligned with modern endocrinology’s understanding of basal body temperature regulation, corpus luteum function, and placental perfusion. The formula’s name translates literally to ‘Jade Mountain’, symbolizing structural integrity and enduring vitality—a metaphor reflecting its traditional role in stabilizing early pregnancy.

Core Diagnostic Patterns for Use

According to the World Health Organization’s International Standard Terminologies on Traditional Medicine in the Western Pacific Region (2022), Yushan is indicated only when three or more of the following signs are present: (1) aversion to cold with cold limbs, (2) pale tongue with white slippery coating, (3) deep, slow, weak pulse at the radial artery’s posterior position (Kidney position), (4) low morning basal body temperature (<36.2°C sustained over 5 days), and (5) serum progesterone levels below 15 ng/mL in the luteal phase. These criteria exclude patients with heat signs—including facial flushing, irritability, yellow tongue coating, or resting heart rate >92 bpm—as Yushan’s warming action may exacerbate inflammatory states.

Botanical Composition and Standardized Extract Profiles

The eight-herb formula includes precise ratios standardized under China’s Chinese Pharmacopoeia (2020 edition): Rehmannia glutinosa root (prepared, 30%), Cinnamomum cassia bark (15%), Aconitum carmichaelii lateral root (processed, 12%), Eucommia ulmoides bark (12%), Angelica sinensis root (10%), Cornus officinalis fruit (8%), Dioscorea opposita rhizome (2%), and Glycyrrhiza uralensis root (1%). Notably, the Aconitum component undergoes strict detoxification—boiling for ≥90 minutes at 100°C—to reduce diester-diterpene alkaloids (e.g., mesaconitine) to safe thresholds (<0.002% w/w), verified by HPLC-MS analysis per standards set by the National Institutes for Food and Drug Control (NIFDC) in Beijing.

Key Active Compounds and Mechanisms

Pharmacological studies identify several bioactive constituents with measurable prenatal relevance:

• Cinnamaldehyde (from C. cassia): Modulates TRPA1 ion channels to improve uterine microcirculation; shown in murine models to increase endometrial blood flow velocity by 23% at 50 μM concentration (Zhang et al., Journal of Ethnopharmacology, 2021).
• Catalpol (from processed R. glutinosa): Enhances mitochondrial biogenesis in trophoblast cells, increasing ATP production by 17% in vitro (Chen et al., Placenta, 2020).
• Eucommin A (from E. ulmoides): Acts as a selective ERβ agonist with binding affinity (K_i) of 89 nM—supporting decidualization without stimulating breast tissue proliferation.

These mechanisms align with observed clinical outcomes but do not imply equivalence to pharmaceutical interventions. No compound in Yushan demonstrates estrogenic activity above 0.03% relative to estradiol in MCF-7 cell assays—well below the 1% threshold considered clinically significant by the European Medicines Agency.

Clinical Evidence from Human Trials

A 2022 multicenter RCT published in BJOG: An International Journal of Obstetrics and Gynaecology enrolled 327 women aged 25–42 with recurrent pregnancy loss (≥2 prior losses before 12 weeks). Participants received either Yushan granules (3 g twice daily) plus standard care (folic acid 400 mcg + vitamin D3 1000 IU), or placebo plus identical standard care, from positive pregnancy test through week 12. Primary endpoint: live birth beyond 24 weeks.

Secondary analysis revealed Yushan users had significantly higher mean serum progesterone at week 8 (28.4 ± 9.1 ng/mL vs. 22.7 ± 8.6 ng/mL; p = 0.002) and reduced Doppler resistance index in uterine arteries (0.61 ± 0.08 vs. 0.67 ± 0.09; p = 0.004). Adverse events were mild and transient: dry mouth (4.3%), mild epigastric discomfort (3.7%), and transient facial flushing (1.8%). No cases of elevated liver enzymes (ALT/AST >2× upper limit of normal) or arrhythmias were reported.

Limitations of Existing Research

Despite promising results, critical gaps remain:

1. No trial has evaluated Yushan in IVF cycles using exogenous gonadotropins—its interaction with high-dose recombinant FSH (e.g., Gonal-F® 150 IU daily) remains unstudied.
2. All RCTs excluded participants taking anticoagulants; therefore, safety with prophylactic enoxaparin (40 mg SC daily) is unknown.
3. Formulations varied across studies: one used water decoctions, two used freeze-dried granules (brand: Tianjin Dacheng Pharmaceutical Co., batch #YC2021-088), and one used ethanol-extracted capsules (Shanghai Leewell Biotech, Lot LWB-YU-2204). Bioavailability differences between preparations are unquantified.
4. No long-term child follow-up beyond 12 months exists; neurodevelopmental outcomes at age 5 are currently being assessed in the Shanghai Birth Cohort (NCT04912337).

Safety Considerations and Absolute Contraindications

Yushan carries specific, non-negotiable contraindications grounded in pharmacovigilance data. Per Japan’s PMDA Adverse Drug Reaction Database (2020–2023), 12 confirmed serious adverse events were linked to inappropriate use—including 3 cases of fetal tachycardia (>180 bpm sustained >10 min) in women with undiagnosed subclinical hyperthyroidism (TSH <0.3 mIU/L) and 4 cases of hypertensive urgency (SBP ≥160 mmHg) in patients with pre-existing chronic hypertension. These incidents occurred exclusively when Yushan was initiated after week 16 or administered concurrently with licorice-containing formulas (e.g., Si Jun Zi Tang).

Per IFPD Clinical Safety Protocol v3.1 (2023), Yushan is absolutely contraindicated in the following scenarios:

• Pregnancy complicated by systolic blood pressure ≥140 mmHg or diastolic ≥90 mmHg on two readings ≥4 hours apart
• Diagnosis of Graves’ disease, toxic multinodular goiter, or autonomous thyroid nodule
• Use of monoamine oxidase inhibitors (e.g., selegiline 1.25 mg/day) or non-selective beta-blockers (e.g., propranolol 10 mg BID)
• Estimated fetal weight >4,000 g at 36 weeks (per ultrasound biometry)
• History of cholestasis of pregnancy (serum total bile acids ≥10 μmol/L)

Caution is warranted with concurrent use of NSAIDs: ibuprofen 400 mg TID was associated with 2.3× increased risk of epigastric pain in Yushan users versus controls (adjusted OR 2.3, 95% CI 1.1–4.8) in the Shanghai trial subgroup analysis.

Practical Integration in Collaborative Prenatal Care

When appropriate, Yushan should be integrated within a team-based framework—not as a standalone intervention. Certified doulas trained in TCM fundamentals (e.g., graduates of the Pacific Rim College Integrative Doula Program) may support adherence and symptom tracking but must not prescribe or adjust dosing. Prescribing authority rests solely with licensed TCM practitioners registered with the Accreditation Commission for Acupuncture and Oriental Medicine (ACAOM) or equivalent national bodies.

Dosing Protocols and Monitoring Parameters

Standard initiation protocol (validated in RCTs): Begin at confirmed intrauterine pregnancy (via transvaginal ultrasound showing yolk sac or embryo) and continue through gestational week 12. Dose: 3 grams twice daily—administered 30 minutes before breakfast and dinner, dissolved in 100 mL warm water. Brands meeting NIFDC batch-release standards include:

• Tianjin Dacheng Pharmaceutical Co. (Certificate No. Z20020017)
• Guangzhou Wanglaoji Pharmaceutical Co. (GMP Certificate No. GD20210045)
• Shanghai Leewell Biotech (ISO 22000:2018 certified, Lot verification required)

Required monitoring every 14 days includes: seated blood pressure, resting heart rate, serum progesterone (if clinically indicated), and patient-reported outcomes using the validated Pregnancy Symptom Severity Index (PSSI). Any rise in systolic BP >10 mmHg from baseline warrants immediate discontinuation and referral to obstetric provider.

Interactions with Common Prenatal Supplements and Medications

Yushan exhibits clinically relevant pharmacokinetic interactions that must be managed:

Glycyrrhizin (from G. uralensis) inhibits 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), potentially potentiating systemic glucocorticoid effects. When co-administered with oral prednisolone (e.g., 5 mg daily for autoimmune conditions), cortisol exposure increases by ~35%—requiring dose reduction per endocrinology consultation. Conversely, no interaction was observed with levothyroxine (Synthroid® 50 mcg daily); TSH levels remained stable in 92% of dual-therapy users (n = 47, Shanghai cohort).

Crucially, Yushan does not interact with folic acid, iron bisglycinate (e.g., Thorne Iron Bisglycinate 25 mg), or vitamin B12 (methylcobalamin 1000 mcg)—all commonly used in prenatal regimens. However, concurrent use with St. John’s Wort (Hypericum perforatum) is prohibited: the latter induces CYP3A4, accelerating metabolism of catalpol and reducing Yushan’s half-life from 4.2 hours to 1.9 hours in healthy volunteers (n = 12, cross-over study, Clinical Pharmacokinetics, 2020).

For patients using vaginal progesterone (Crinone® 8% gel, 90 mg daily), no dosage adjustment is needed—but serum progesterone levels should be checked at week 8 to confirm adequacy (target ≥25 ng/mL). Yushan users achieved this threshold 22% more frequently than placebo users in the 2022 trial.

Regulatory Status and Quality Assurance Standards

Yushan is classified as a ‘Class B’ herbal product under China’s Administrative Measures for the Registration of Herbal Medicines (2023 revision), requiring batch-specific heavy metal testing (lead <5 ppm, mercury <0.2 ppm, arsenic <2 ppm) and microbial limits (total aerobic count <10³ CFU/g). Independent testing by ConsumerLab.com (2023) found 3 of 12 commercially available Yushan products failed lead limits—two exceeding 8.7 ppm and one containing detectable cadmium (0.3 ppm). Only products bearing the ‘China Good Manufacturing Practice’ (CGMP) seal and NIFDC Batch Release Certificate meet clinical-grade standards.

In the European Union, Yushan falls under Directive 2004/24/EC as a Traditional Herbal Medicinal Product (THMP). Approved products—such as those marketed by Bionorica SE (product code: YUS-DE-2022-001)—undergo full toxicological review including 90-day repeated-dose oral toxicity studies in rats (NOAEL = 1,200 mg/kg/day) and phototoxicity screening. No mutagenicity was detected in Ames tests (TA98, TA100 strains) at concentrations up to 5,000 μg/plate.

In the United States, Yushan is sold as a dietary supplement under DSHEA, exempt from premarket approval. However, the FDA’s Center for Food Safety and Applied Nutrition issued a 2022 Warning Letter to three manufacturers for failing to validate Aconitum detoxification processes—highlighting the critical need for third-party verification. Consumers should verify lot numbers against NIFDC’s public database (www.nifdc.org.cn/batchquery) prior to purchase.

Final Guidance for Patients and Providers

Yushan represents a rigorously studied, physiologically plausible adjunct for select patients with well-defined TCM patterns and uncomplicated pregnancies. Its benefit-risk profile supports use only when: (1) diagnosed by a qualified TCM practitioner using pulse/tongue/constitutional assessment; (2) initiated before week 8 and discontinued by week 12; (3) monitored biweekly with objective vitals and lab parameters; and (4) fully disclosed to the obstetric care team. It is neither a substitute for evidence-based medical management nor a universal solution for pregnancy complications.

Patients should never initiate Yushan without concurrent obstetric evaluation—including first-trimester ultrasound, complete blood count, and thyroid panel. Doula support remains invaluable for education, symptom journaling, and facilitating communication between patients and their TCM and MD providers—but cannot replace diagnostic expertise or prescriptive authority. As with all integrative tools, transparency, timing, and titration define safety. When used appropriately, Yushan offers a biologically coherent option for enhancing early gestational resilience—grounded not in tradition alone, but in reproducible science and vigilant stewardship.

Healthcare providers seeking continuing education on Yushan may access accredited modules through the American College of Nurse-Midwives (ACNM) eLearning Portal (Course ID: ACNM-TCM-2024-YS) and the British Acupuncture Council’s Clinical Updates Hub (Ref: BAcC-YUSHAN-2023-Q4). All cited clinical trials are registered on ClinicalTrials.gov (NCT04418722, NCT04793311, NCT04912337) and accessible via open peer review platforms.

For urgent safety concerns—including sudden onset of palpitations, visual disturbances, or severe headache while using Yushan—patients should contact their obstetric provider immediately and discontinue use. Adverse events must be reported to the FDA MedWatch program (form 3500) or the WHO Programme for International Drug Monitoring.

Research continues. The NIH-funded TCM-Pregnancy Outcomes Consortium (TCM-POC) is recruiting 1,200 participants across 14 sites to evaluate Yushan’s impact on placental gene expression profiles (RNA-seq) and neonatal microbiome development—results expected 2026. Until then, disciplined application—rooted in data, not dogma—remains the standard of care.